Crizotinib in<i>ALK</i>-Rearranged Inflammatory Myofibroblastic Tumor
James E. Butrynski(Harvard University), Geoffrey I. Shapiro(Brigham and Women's Hospital), Marc Ladanyi(Memorial Sloan Kettering Cancer Center), Pasi A. Jänne(Harvard University), Scott J. Rodig(Brigham and Women's Hospital), Keith D. Wilner(Pfizer (United States)), Paola Dal Cin(Brigham and Women's Hospital), Robert G. Maki(Memorial Sloan Kettering Cancer Center), Nikhil H. Ramaiya(Brigham and Women's Hospital), James G. Christensen, Jason L. Hornick(Harvard University), Cristina R. Antonescu(Memorial Sloan Kettering Cancer Center), Jeffrey W. Clark(Massachusetts General Hospital), David R. D’Adamo(Eisai (United States)), Eunice L. Kwak(Harvard University), Marzia Capelletti(Caris Life Sciences (United States)), Suresh C. Jhanwar(Memorial Sloan Kettering Cancer Center), George D. Demetri(American Society of Clinical Oncology)
Cited by 871
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k